Netherlands· NL-74ec1d97928e

Modalim, tabletten 100 mg

A ciprofibrate product containing ciprofibraat, registered in Netherlands by Sanofi B.V.. The same ATC class is registered in 5 of our 19 countries.

ATC C10AB08

Checked against CBG-MEB (Netherlands) on September 29, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about ciprofibraatAnswers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Ciprofibrate is registered in 5 of 19 countries.

Countries holding a registration under ATC C10AB08 (ciprofibrate), each read from that country’s own register.

This record: Netherlands, from CBG-MEB (Netherlands)
3 of them publish a price we can compare per daily dose

Search ciprofibrate products by name

Ciprofibrate · ATC C10AB08

5 / 19 countries

Belgiumprice
Franceprice
Netherlands
Polandprice
United Kingdom

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)

Active substance: CIPROFIBRAAT
Manufacturer: Sanofi B.V.
Country: Netherlands (NL)
ATC code: C10AB08
ATC class: Ciprofibrate
Defined daily dose: 0.1 g, O
Reimbursed: Not published by this register
Source register: CBG-MEB (Netherlands)
Last checked: September 29, 2026

Packs & prices · 1

cbg_meb_id
17863

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Ciprofibrate in 4 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All ciprofibrate products

Authorised across Europe · EMA

The same active substance is authorised in 4 EEA countries. Names it is sold under:

Bulgaria · Липанор
France · Ciprofibrate Arrow, Ciprofibrate Biogaran
United Kingdom (Northern Ireland) · Ciprofibrate Accord-Uk, Ciprofibrate Zentiva
Poland · Lipanor

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/2aeae9b7-886a-446a-9f30-eb3dbb2d57d7
GET /v1/drugs/2aeae9b7-886a-446a-9f30-eb3dbb2d57d7?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tablet",
  "route": "Oraal gebruik",
  "soort": "RVG",
  "source": "cbg_meb",
  "smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h17863_smpc.pdf",
  "strength": null,
  "atc_label": "Ciprofibrate",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg17863",
  "excipients": [
    "CELLULOSE, MICROKRISTALLIJN (E 460(i))",
    "HYPROMELLOSE (E 464)",
    "LACTOSE 1-WATER",
    "MAÏSZETMEEL",
    "NATRIUMLAURILSULFAAT",
    "STEROTEX K (RI)"
  ],
  "substances": [
    "CIPROFIBRAAT"
  ],
  "leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h17863.pdf",
  "authorised_at": "1995/03/28",
  "procedure_number": null,
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "17863",
  "additional_monitoring": "N"
}

API reference MCP server Plans

See everything about ciprofibrate.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console